Compare BBAR & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | MMED |
|---|---|---|
| Founded | 1886 | 1983 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 1997 | 2026 |
| Metric | BBAR | MMED |
|---|---|---|
| Price | $21.18 | $15.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $22.56 |
| AVG Volume (30 Days) | 714.8K | ★ 1.1M |
| Earning Date | 05-20-2026 | 06-03-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.32 | $15.99 |
| Revenue Next Year | $11.04 | $10.00 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $10.65 |
| 52 Week High | $22.47 | $17.86 |
| Indicator | BBAR | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 57.03 |
| Support Level | $17.03 | $10.68 |
| Resistance Level | $21.92 | $15.74 |
| Average True Range (ATR) | 1.13 | 0.81 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 70.99 | 60.61 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.